# Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

> **NCT05241132** · PHASE2 · UNKNOWN · sponsor: **Wei Xu** · enrollment: 27 (estimated)

## Conditions studied

- Cancer of Unknown Primary
- Bone Cancer Metastatic
- Tislelizumab
- Gene Mutation-Related Cancer
- Immune Evasion, Tumor
- Chemotherapy Effect

## Interventions

- **DRUG:** Tislelizumab plus chemotherapy

## Key facts

- **NCT ID:** NCT05241132
- **Lead sponsor:** Wei Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-12
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-10-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241132, "Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05241132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*